Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: PROCEDURE: Surgery for harvesting tumor-draining lymph nodes|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|BIOLOGICAL: Camrelizumab|DRUG: Chemotherapeutic drug, ADC or PARP inhibitor
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University